{
    "mainTopic": {
        "title": "Arachidonic Acid Metabolism",
        "content_info": "",
        "subTopics": [
            {
                "title": "Arachidonic acid cascade: Derivates, enzimes and pathways",
                "quizzes": [
                    {
                        "question": "Which enzyme is primarily responsible for the release of arachidonic acid from membrane phospholipids, initiating the arachidonic acid cascade?",
                        "goodAnswer": "Phospholipase A2 (PLA2) enzymes, specifically cytosolic PLA2, are activated by various stimuli to hydrolyze membrane phospholipids and release arachidonic acid.",
                        "wrongAnswer_1": "Cyclooxygenase (COX) enzymes, particularly COX-1 and COX-2, are activated by growth factors to esterify arachidonic acid into membrane phospholipids.",
                        "wrongAnswer_2": "Lipoxygenase (LOX) enzymes, mainly 5-LOX and 12-LOX, are responsible for the initial oxidation of arachidonic acid, leading to its release from membranes.",
                        "wrongAnswer_3": "Sphingomyelinase enzymes, including neutral and acidic sphingomyelinases, are activated by cytokines to cleave sphingomyelin and release arachidonic acid.",
                        "wrongAnswer_4": "Acyl-CoA synthetase enzymes, especially long-chain acyl-CoA synthetases, are responsible for ligating arachidonic acid to CoA, thus releasing it from the membrane."
                    },
                    {
                        "question": "In the cyclooxygenase (COX) pathway of arachidonic acid metabolism, what is the immediate product formed after COX enzymes act on arachidonic acid?",
                        "goodAnswer": "Prostaglandin G2 (PGG2) is the initial product formed by the cyclooxygenase activity of COX enzymes, which is then rapidly converted to Prostaglandin H2 (PGH2).",
                        "wrongAnswer_1": "Prostaglandin E2 (PGE2) is the primary initial product of COX enzymes, directly formed from arachidonic acid before further metabolism into other prostaglandins.",
                        "wrongAnswer_2": "Thromboxane A2 (TXA2) is the first stable product generated by COX enzymes, immediately following the release of arachidonic acid from membrane phospholipids.",
                        "wrongAnswer_3": "Leukotriene A4 (LTA4) is an unstable epoxide formed by COX enzymes, serving as a precursor for all prostaglandins, thromboxanes, and prostacyclins.",
                        "wrongAnswer_4": "Prostacyclin (PGI2) is the initial cyclic endoperoxide product generated by COX enzymes, which then isomerizes to form PGG2 and subsequently PGH2."
                    },
                    {
                        "question": "Which of the following represents the correct enzymatic pathway for the synthesis of leukotrienes from arachidonic acid?",
                        "goodAnswer": "Arachidonic acid -> 5-Lipoxygenase (5-LOX) -> 5-Hydroperoxyeicosatetraenoic acid (5-HPETE) -> Leukotriene A4 (LTA4) -> Leukotrienes (LTB4, LTC4, LTD4, LTE4)",
                        "wrongAnswer_1": "Arachidonic acid -> Cyclooxygenase-1 (COX-1) -> Prostaglandin G2 (PGG2) -> Prostaglandin H2 (PGH2) -> Leukotrienes (LTB4, LTC4, LTD4, LTE4)",
                        "wrongAnswer_2": "Arachidonic acid -> Phospholipase A2 (PLA2) -> Prostaglandin H2 (PGH2) -> 5-Lipoxygenase (5-LOX) -> Leukotrienes (LTB4, LTC4, LTD4, LTE4)",
                        "wrongAnswer_3": "Arachidonic acid -> 12-Lipoxygenase (12-LOX) -> 12-Hydroperoxyeicosatetraenoic acid (12-HPETE) -> Lipoxins (LXA4, LXB4) -> Leukotrienes (LTB4, LTC4, LTD4, LTE4)",
                        "wrongAnswer_4": "Arachidonic acid -> Epoxygenase enzymes -> Epoxyeicosatrienoic acids (EETs) -> Leukotriene A4 (LTA4) -> Leukotrienes (LTB4, LTC4, LTD4, LTE4)"
                    },
                    {
                        "question": "What are the primary enzymes responsible for the synthesis of prostaglandins and thromboxanes from Prostaglandin H2 (PGH2)?",
                        "goodAnswer": "Specific isomerases and synthases, such as prostaglandin synthases (e.g., PGE synthase, PGF synthase) and thromboxane synthase, act on PGH2 to produce various prostaglandins and thromboxanes.",
                        "wrongAnswer_1": "Lipoxygenases (LOX) like 5-LOX and 12-LOX directly convert PGH2 into prostaglandins and thromboxanes through oxidative mechanisms in different cell types.",
                        "wrongAnswer_2": "Phospholipase C (PLC) and Phospholipase D (PLD) enzymes hydrolyze PGH2 to release free prostaglandins and thromboxanes for immediate biological action.",
                        "wrongAnswer_3": "Acyltransferases and acylhydrolases modify PGH2 by adding or removing fatty acid chains, resulting in the formation of prostaglandins and thromboxanes.",
                        "wrongAnswer_4": "Cyclooxygenases (COX-1 and COX-2) catalyze the conversion of PGH2 into prostaglandins and thromboxanes by further oxidation and cyclization reactions."
                    }
                ]
            },
            {
                "title": "Biological Functions of Arachidonic Acid Products",
                "quizzes": [
                    {
                        "question": "Which eicosanoid is primarily responsible for promoting platelet aggregation and vasoconstriction, playing a critical role in hemostasis and thrombosis?",
                        "goodAnswer": "Thromboxane A2 (TXA2), predominantly produced by platelets, is a potent inducer of platelet aggregation and vasoconstriction, essential for blood clotting.",
                        "wrongAnswer_1": "Prostacyclin (PGI2), mainly synthesized by endothelial cells, strongly promotes platelet aggregation and vasoconstriction, thereby regulating blood flow and pressure.",
                        "wrongAnswer_2": "Prostaglandin E2 (PGE2), widely produced in various tissues, is the primary eicosanoid mediating platelet aggregation and vasoconstriction during inflammation.",
                        "wrongAnswer_3": "Leukotriene B4 (LTB4), primarily produced by leukocytes, induces platelet aggregation and vasoconstriction, contributing to inflammatory responses in blood vessels.",
                        "wrongAnswer_4": "Lipoxin A4 (LXA4), generated during inflammation resolution, indirectly promotes platelet aggregation and vasoconstriction to facilitate tissue repair processes."
                    },
                    {
                        "question": "What is the major biological function attributed to Leukotriene B4 (LTB4) in the context of inflammation and immune response?",
                        "goodAnswer": "LTB4 is a potent chemoattractant for neutrophils and other leukocytes, stimulating their migration to inflammatory sites and enhancing their activation and degranulation.",
                        "wrongAnswer_1": "LTB4 primarily functions to resolve inflammation by promoting the efferocytosis of apoptotic neutrophils and suppressing pro-inflammatory cytokine production.",
                        "wrongAnswer_2": "LTB4 is a potent vasodilator that increases blood flow to inflamed tissues and reduces leukocyte adhesion to endothelial cells, thereby limiting inflammation.",
                        "wrongAnswer_3": "LTB4 mainly acts as an analgesic, reducing pain sensation at inflammatory sites by inhibiting the release of pro-inflammatory mediators like prostaglandins.",
                        "wrongAnswer_4": "LTB4's primary role is to stimulate the production of mucus in the respiratory tract, protecting epithelial cells from damage during inflammatory responses."
                    },
                    {
                        "question": "How do prostaglandins, particularly PGE2, contribute to the physiological process of fever during infection or inflammation?",
                        "goodAnswer": "PGE2 acts on the hypothalamus to increase the thermoregulatory set point, leading to fever by promoting heat conservation and heat generation mechanisms.",
                        "wrongAnswer_1": "PGE2 inhibits the hypothalamus, causing a decrease in body temperature as a protective mechanism against hyperthermia during inflammation.",
                        "wrongAnswer_2": "PGE2 directly stimulates skeletal muscle contraction to generate heat and induce shivering, thereby elevating body temperature in febrile conditions.",
                        "wrongAnswer_3": "PGE2 acts on peripheral nerve endings to increase sensitivity to cold, leading to a subjective feeling of chills and subsequent fever development.",
                        "wrongAnswer_4": "PGE2 promotes sweating and vasodilation to dissipate heat, counteracting fever and maintaining normal body temperature during infection."
                    },
                    {
                        "question": "What is the primary role of Prostacyclin (PGI2) in the cardiovascular system, particularly in opposition to the actions of Thromboxane A2 (TXA2)?",
                        "goodAnswer": "PGI2 is a potent vasodilator and inhibitor of platelet aggregation, counteracting TXA2's vasoconstrictive and pro-aggregatory effects, thus maintaining vascular homeostasis.",
                        "wrongAnswer_1": "PGI2 enhances vasoconstriction and promotes platelet aggregation, synergizing with TXA2 to ensure rapid blood clotting at sites of vascular injury.",
                        "wrongAnswer_2": "PGI2 primarily functions as a platelet agonist, stimulating platelet activation and aggregation to initiate thrombus formation in response to vascular damage.",
                        "wrongAnswer_3": "PGI2 is a potent bronchoconstrictor and promotes leukocyte infiltration into blood vessels, contributing to inflammatory responses in the cardiovascular system.",
                        "wrongAnswer_4": "PGI2 mainly regulates blood pressure by increasing renin release from the kidneys, leading to angiotensin II production and subsequent vasoconstriction."
                    }
                ]
            },
            {
                "title": "NSAIDS",
                "quizzes": [
                    {
                        "question": "What is the fundamental mechanism of action by which Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) exert their therapeutic effects?",
                        "goodAnswer": "NSAIDs primarily inhibit cyclooxygenase (COX) enzymes (COX-1 and COX-2), reducing the production of prostaglandins and thromboxanes, thereby decreasing inflammation, pain, and fever.",
                        "wrongAnswer_1": "NSAIDs directly block the action of phospholipase A2 (PLA2), preventing the release of arachidonic acid from membrane phospholipids and halting the entire eicosanoid cascade.",
                        "wrongAnswer_2": "NSAIDs activate lipoxygenase (LOX) enzymes, shifting the arachidonic acid metabolism towards leukotriene production, which paradoxically reduces inflammation.",
                        "wrongAnswer_3": "NSAIDs stimulate the production of corticosteroids, mimicking their anti-inflammatory actions by increasing the synthesis of lipocortins and inhibiting PLA2.",
                        "wrongAnswer_4": "NSAIDs antagonize prostaglandin receptors, preventing prostaglandins from binding to their receptors and eliciting inflammatory responses, without affecting prostaglandin synthesis."
                    },
                    {
                        "question": "How do selective COX-2 inhibitors differ from traditional non-selective NSAIDs in terms of their mechanism and potential side effects?",
                        "goodAnswer": "Selective COX-2 inhibitors primarily target COX-2, reducing prostaglandin production at inflammatory sites while sparing COX-1, potentially leading to fewer gastrointestinal side effects but increased cardiovascular risks.",
                        "wrongAnswer_1": "Selective COX-2 inhibitors block both COX-1 and COX-2 with equal potency, but they are metabolized faster, resulting in a shorter duration of action and reduced side effects overall.",
                        "wrongAnswer_2": "Selective COX-2 inhibitors enhance COX-1 activity while inhibiting COX-2, leading to a balanced reduction in inflammation without affecting gastrointestinal or cardiovascular systems.",
                        "wrongAnswer_3": "Selective COX-2 inhibitors do not inhibit COX enzymes; instead, they directly block prostaglandin receptors, thus avoiding both gastrointestinal and cardiovascular side effects.",
                        "wrongAnswer_4": "Selective COX-2 inhibitors are prodrugs that are converted to non-selective COX inhibitors in the body, effectively having the same mechanism and side effect profile as traditional NSAIDs."
                    },
                    {
                        "question": "What are the primary therapeutic applications of NSAIDs, considering their mechanism of action and pharmacological properties?",
                        "goodAnswer": "NSAIDs are widely used for managing mild to moderate pain, reducing fever, and alleviating inflammation associated with conditions like arthritis, musculoskeletal injuries, and dysmenorrhea.",
                        "wrongAnswer_1": "NSAIDs are primarily used for treating severe bacterial infections due to their potent antibacterial properties and ability to enhance antibiotic efficacy.",
                        "wrongAnswer_2": "NSAIDs are the first-line treatment for chronic asthma and allergic reactions because of their ability to inhibit leukotriene production and bronchodilation.",
                        "wrongAnswer_3": "NSAIDs are commonly used to manage hypertension and heart failure due to their vasodilatory effects and ability to reduce blood pressure.",
                        "wrongAnswer_4": "NSAIDs are mainly indicated for the treatment of peptic ulcers and gastroesophageal reflux disease due to their protective effects on the gastric mucosa."
                    },
                    {
                        "question": "Which of the following is a major gastrointestinal side effect commonly associated with the use of non-selective NSAIDs, and why does it occur?",
                        "goodAnswer": "Gastric ulceration and bleeding are common because non-selective NSAIDs inhibit COX-1, which is important for maintaining gastric mucosal integrity and protection.",
                        "wrongAnswer_1": "Constipation and bowel obstruction are frequent side effects due to NSAIDs' inhibition of intestinal motility and fluid secretion in the gastrointestinal tract.",
                        "wrongAnswer_2": "Liver damage and hepatitis are prevalent because NSAIDs are directly toxic to hepatocytes and induce inflammation in the liver parenchyma.",
                        "wrongAnswer_3": "Pancreatitis and pancreatic enzyme insufficiency are common because NSAIDs stimulate pancreatic enzyme secretion and cause inflammation of the pancreas.",
                        "wrongAnswer_4": "Esophageal varices and gastroesophageal reflux are typical side effects due to NSAIDs weakening the lower esophageal sphincter and increasing gastric acid production."
                    },
                    {
                        "question": "How do NSAIDs affect platelet function, and what is the clinical significance of this effect, particularly in relation to aspirin?",
                        "goodAnswer": "NSAIDs, especially non-selective ones, can inhibit platelet aggregation by reducing thromboxane A2 production, increasing the risk of bleeding, similar to but less potent than aspirin's irreversible COX-1 inhibition.",
                        "wrongAnswer_1": "NSAIDs enhance platelet aggregation and increase the risk of thrombosis by stimulating thromboxane A2 production, counteracting the antiplatelet effects of aspirin.",
                        "wrongAnswer_2": "NSAIDs have no significant effect on platelet function as they primarily target COX-2 in platelets and do not affect thromboxane A2 synthesis or platelet aggregation.",
                        "wrongAnswer_3": "NSAIDs induce irreversible inhibition of COX-2 in platelets, leading to a prolonged antiplatelet effect that is more potent and longer-lasting than aspirin's effect on COX-1.",
                        "wrongAnswer_4": "NSAIDs promote platelet activation and adhesion to the endothelium, increasing the risk of both bleeding and thrombosis depending on the specific NSAID and clinical context."
                    }
                ]
            }
        ]
    }
}
